Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

PURPOSE: We report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)–selective inhibi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Juric, Dejan, Rodon, Jordi, Tabernero, Josep, Janku, Filip, Burris, Howard A., Schellens, Jan H.M., Middleton, Mark R., Berlin, Jordan, Schuler, Martin, Gil-Martin, Marta, Rugo, Hope S., Seggewiss-Bernhardt, Ruth, Huang, Alan, Bootle, Douglas, Demanse, David, Blumenstein, Lars, Coughlin, Christina, Quadt, Cornelia, Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5920739/
https://ncbi.nlm.nih.gov/pubmed/29401002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.72.7107
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados